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Although the dermal lesions of chronic discoid lupus exythematosus (1) were
described more than a hundred years ago, many investigators feel that an ideal,
specific diagnostic test is still lacking. Among the predisposing factors of this dis-
ease, photosensitivity seems to be of prime importance. Jessar and co-workers (2)
claimed that sensitivity to sunlight was a precipitating factor in 272 of their
cases, and Gold's observations (3) led him to the same conclusion.
Page (4) treated 18 cases, varying from chronic to acute discoid L.E. (in one
case associated with rheumatoid arthritis), with mepacrine (quinacrinet), and
noted improvement in 17 cases. In discussing the possible mode of action he
pointed out that the drug reduced the dermal photosensitivity of his patients. He
could, in fact, demonstrate a significant change in the reaction time to a minimal
erythema dose between controls and patients who had received medication for
ten days. Denzer and Blumenthal (5) have demonstrated that photosensitivity
is a common symptom in discoid L.E., and that the toxicosis is a reaction of the
ensuing peculiarly susceptible constitutional state.
It is interesting to speculate on the fact that the incidence of the disease is
higher (88 per cent) in females (6, 7), since the lesions are confined almost
entirely to those portions of the body which are not shielded by clothing. Familial
tendencies are also noted (1). The so-called butterfly pattern of bilaterally sym-
metrical distribution, usually involving the face and occurring also on the arms
and hands, which are typical sites for the eruptions, leads to the inescapable con-
clusion that the dermal manifestations of the disease are in some way associated
with the effect of light on the exposed body surfaces.
It had been observed earlier that certain antimalarials such as quinacrine,
(Atabrine®), which are intrinsically deeply colored, give visible evidence of
deposition in the skin. This observation presumably led the Russian investigator
Prokoptchouk (8) in 1940 to a trial of this drug in the treatment of 35 patients
affected with discoid L.E. The following year another Russian clinician, Sorinson
(9), undertook the treatment of L.E. in 70 patients, and noted favorable results
after two courses of quinacrine. This management of the disease became well-
known in several European countries, including Germany (10), Italy (11), and
Great Britain (4). It was mainly the success which Page obtained in 17 of 18
patients (4) that caused clinicians in the United States to give serious thought to
this type of chemotherapy. Encouraged by Page's report, O'Leary and collabora-
tors (12) at the Mayo Clinic began the systemic treatment of L.E. with anti-
malarials in 1952.
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The efficiency of quinacrine in the management of discoid L.E. has since been
confirmed by many investigators. The reports of Rhodes and Allende (13),
Somerville et al (14), Buchanan et at (15), and Michelson (16) may be regarded
as typical. The success with quinacrine led naturally to the trial of other anti-
malarial drugs in the hope of avoiding the visible staining of the skin which is so
characteristic of the former. Chloroquine* was found to possess the desired
effect. Goldman et at (17) pointed out that it produced only an insignificant inci-
dence of side effects, but stated that the response was slower than obtained with
the acridine type of compound. Shee (18) successfully cleared up chronic discoid
L.E. in patients who had been afflicted with the disease for as long as 14 years.
Rogers and Finn (19) compared the two drugs and obtained satisfactory results
with both. Similarly, Pillsbury and Jacobson (20), treated 16 chronic discoid
L.E. patients with chioroquine and obtained good results.
Recently, Cornbleet (21) increased the armamentarium of antimalarials for
the management of L.E. by reporting on another 4-aminoquinoline type drug,
i.e. hydroxychloroquine.t All of his seven patients responded favorably to the
therapy. Cornbleet's findings were confirmed on a larger series of patients by
Lewis and Frumess (22). They were impressed with the rapidity of therapeutic
response. Doses ranging from 600 to 2000 mg./day of hydroxychioroquine were
administered to 40 patients by Mullins et at (23), who stressed the fact that
larger doses of this drug seemed to be necessary, but also that patients who could
not tolerate chloroquine could be managed successfully with the hydroxy analog.
Like other authors, they postulated that the drug must be deposited in the skin, at
the site of the lesions, in order to exert its activity.
In order to validate this sun-screening concept, one would need data on the
skin distribution of the three antimalarials which have been discussed above. The
fact that quinacrine localizes extensively in the skin is well-known, and qualita-
tive statements to this effect have appeared many times in the literature (24 and
25). As regards quantitative data, Heeht (26) studied the distribution of quina-
crine in the organs of mice, guinea pigs, cats, and rabbits. In mice which received
200 mg./kg. of the musonate (methane sulfonate) s.c. and were killed 48 hrs.
later he found a concentration of 35 mg. per kg. of skin. In rabbits which received
15 mg. of the dihydrochioride per kg. i.m. and were killed 11 hrs. later he found
7.5 mg. per kg. of skin, while in rabbits which received 50 mg. of the dihydro-
chloride per kg. orally for 10 days and were killed 6 hrs. after the last dose he
found 110 mg. per kg. of skin. The dosage schedules used in guinea pigs and cats
did not result in extensive skin localization. Dearborn et at (27) administered
quinacrine dihydroehloride in doses of 50 mg./kg./day orally to dogs for 14 days,
and found skin concentrations ranging from 15 to 51 mg. per kg. of skin on the
14th day. After giving 5 mg. of quinacrine dihydrochioride per kg. per day for
78 days, they found skin concentrations of 4—5 mg./kg. Barlow, Auerbach and
Rivenburg (28) noted obvious concentrations of quinacrine in the skin of rats
medicated repeatedly with the drug, but did not determine the exact amounts
* Available from Winthrop Laboratories, under the trade-name of Aralen.
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present. The Army Malaria Research Unit at Oxford University noted (29) the
presence of quinacrine in the hair and perspiration of dogs and rats medicated
with the drug, but did not determine skin concentrations. Concentrations of
quinacrine in the skin of man, following its oral administration, have been
recorded by Lange and Matzner (30) in arbitrary units.
There are several reports in the literature on the distribution of chioroquine
in the tissues of such species as dog, monkey, and rat (31, 32). Its widespread
distribution would imply its presence in skin, but this tissue was not included
among those studied. Data on chloroquine and hydroxychloroquine (33) indicate
that their tissue distribution is quite similar; the species studied were dogs and
rats. However, again, skin had not been included in the tissues studied; therefore
it was necessary to obtain this information. Quinacrine was included in the
experiment so that strictly comparable data would be available.
EXPERIMENTAL
Male white rats weighing 140—160 gm. were medicated according to two dosage
schemes: group A received orally 5 mg./kg. of the drug (calculated as base, but
given as the diphosphate salt of chloroquine and hydroxychloroquine, and as
the dihydrochioride of quinacrine) at zero hrs., followed by 2.5 mg./kg. at 8 hrs.
and 2.5 mg./kg. at 24 hrs. Group B received 15 mg./kg. of the drug at zero hrs.,
followed by the same dose at 8 and 24 hrs. The total dose for group A, therefore,
was 10 mg. base/kg., and for group B, 45 mg. base/kg. The animals were killed
2 hrs. after the last dose, and analyses of liver and skin were made. The skin was
prepared by removing most of the hair with an electric clipper, and then shaving
as cleanly as possible. Both tissues were homogenized in water, the extracts were
made alkaline, shaken with ethylene dichloride, and the drug concentrations
were determined as follows: quinacrine by the method of Brodie and Udenfriend
TABLE I
Skin and liver concentrations (as mg. base/kg. wet weight) of some antimalarials in rats
following the oral administration of 3 doses in 24 hrs.*
Chioroquine Ilydroxychioroquine Quinacrine
Skin Liver Skin Liver Skin Liver
A. Total dose = 10 mg. base/kg.
1.6 0.19f 9.5 0.62
Ratio, skin/liver
0.17
2.5 0.28 11.0 0.36
0.23
4.0 0.4 31.7 2.7
0.13
B. Total dose = 45 mg. base/kg.
11.5 1.8 63 3.0
Ratio, skin/liver
0.18
5.9 0.31 39.3 8.7
0.15
15.3 1.3 140 11
0.11
* Animals killed at the 26th hour.
f Concentrations are recorded as mean There were 6 animals per group.
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FIG. 1. Ultraviolet absorption spectra of quinacrine, chioroquine and hydroxychloro-
quine salts in water.
(34); chloroquine and hydroxychloroquine by the procedure of McChesney,
Wyzan and MeAuliff (3ô). The resu]ts are presented in Table I.
Commenis: At the lower dose level (A) the tissue concentrations of chioroquine
are less than those of hydroxychioroquine or quinacrine. The higher skin concen-
tration of quinacrine, as compared to hydroxychloroquine, is accompanied by a
much higher hepatic concentration, with the result that the skin/liver ratio is
greatest for hydroxychioroquine. The marked tendency of quinacrine to localize
>in m&
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FIG. 2. Ultraviolet absorption spectrum of a (ca.) 2:2:1 molar ratio of chloroquine,
hydroxychioroquine and quinacrine salts in water.
in liver is well-known (26—29). The higher dose level (B) produces increases in
quinacrine concentrations in both skin and liver almost exactly proportional to
the increase in dose. However, the higher dose of chioroquine results in increases
in both skin and liver concentrations which are considerably greater than the
increase in dose. At this dose level it gives the highest skin/liver ratio. Hydroxy-
chioroquine does not appear to be as rapidly absorbed as chioroquine on the
higher dose.
220 240 260 280 300 320 340
A in mp..
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At both dose levels, and with all three drugs, the skin concentrations are
approximately 13 per cent of what would be found if the entire dose were ab-
sorbed and retained, with uniform distribution in all of the tissues. In one case
(quinacrine, dose A), the fraction in skin is 20 per cent, on this same basis of
reckoning. These concentrations are as high as one could expect considering the
relatively poor circulation and low water content of the integument, and the
fact that simultaneous degradation and excretion of the compounds tends to deplete
the body stores.
Ultraviolet absorption: The 1JV absorption curves of the three antimalarials are
shown in Fig. 1. The two 4-aminoquinolines have essentially identical spectra,
owing to the identity of the aromatic portion of the molecules. Their maximum
absorption extends beyond the 260m range, with a second doublet in the 330—
350mg region. On the other hand, the acridine molecule has a strong absorption
band at 280m/L, where the absorption of quinolines is minimal. It also has maxima
at 345m and in the visible range (400—460mg), accounting for its yellow color.
Bearing in mind the higher distribution coefficient of quinacrine in the skin, it
can be shown that a most effective actinic screen can be achieved by a combina-
tion therapy with a molar percentage of approximately 40:40:20, the quinacrine
salt being represented by the last figure. The absorption spectrum of this com-
bination of drugs in the actual mole fraction used is shown in Fig. 2. It can
readily be seen that this combination affords a good "sun-screen", cutting out
not only the erythemal but also the tanning rays of the sun's spectrum. We might
add here that the metabolic products of the antimalarials, resulting from the
deamination of the side chain would have equal absorptive power for ultraviolet
light, since, as pointed out above, the absorption is connected with the electron
density of the aromatic rings.
DISCUSSION AND SUMMARY
The present status of diagnosis and treatment of L.E. has been cogently sum-
marized by Dubois (7). His statement reemphasizes the outstanding value of
antimalarial therapy for this disease.
Support for the concept that the antimalarial drugs are effective in lupus
erythematosus as a result of their sun-screening action has been provided here by
the demonstration of their presence in skin, and of their property, particularly in
suitable combination, of absorbing radiation in the region 220—360mg. A formu-
lation containing the three drugs thus has the advantage of absorption of radia-
ation over a wide range of the spectrum, both visible and ultraviolet. Quinacrine
absorbs well where the 4-amino-quinolines absorb rather poorly, and vice versa.
The presence of both chioroquine and hydroxychioroquine in a formulation has
an advantage, derived from the fact that these two compounds have somewhat
different toxicity patterns in both a qualitative and a quantitative sense (36).
This situation makes it possible to surnmate their sun-screening effects without
increasing proportionately the toxicity which might be induced if either of these
two antimalarials were given in double amounts.
Since the trigger of the L.E. syndrome is related to the Koebner phenomenon
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(37), the dramatic success of treatment with antimalarials, and particularly with
combinations of these drugs, is logically attributed to the screening out of harmful
wavelengths, thereby preventing the photonic activation of the process.
Cahn et al (38) have shown that the action spectrum of erythema production
in polymorphous light eruption does not coincide with the absorption spectrum
of chioroquine, but Beal (39) has shown that the sensitivity spectrum of solar
urticaria does coincide with the absorption spectrum of chloroquine. As far as is
known to us, the specific sensitivity spectrum of lupus erythematosus, if it
exists, has not been established. However, Cahn and co-workers indicate that the
antimalarial in their studies "produces its effect by modifying the reaction
pattern.. . in a manner which suppresses the abnormal but not the normal
responses to ultraviolet light in the sunburn spectrum", which would agree
quite well with the rationale here proposed.
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